Comparative Pharmacology
Head-to-head clinical analysis: BUTOCONAZOLE NITRATE versus GRIFULVIN V.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTOCONAZOLE NITRATE versus GRIFULVIN V.
BUTOCONAZOLE NITRATE vs GRIFULVIN V
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Binds to microtubule-associated proteins and disrupts fungal mitotic spindle formation, thereby inhibiting fungal cell division. It also interferes with fungal nucleic acid synthesis.
Intravaginal administration: 100 mg (one applicatorful of 2% cream) once daily for 3 days; or 100 mg (one suppository) once daily for 3 days; or 5 g (one applicatorful of 4% cream) as a single dose.
500 mg orally once daily (non-microsize formulation) or 250 mg twice daily; typical duration is 4-8 weeks for tinea capitis, 2-6 weeks for tinea corporis, 4-6 weeks for tinea pedis.
None Documented
None Documented
Terminal half-life is approximately 21–24 hours, supporting once-daily or twice-weekly dosing for vaginal candidiasis.
Terminal half-life: 9–24 hours. Clinical context: Steady-state achieved in 2–5 days; prolonged in hepatic impairment.
Primarily hepatic metabolism with <5% excreted unchanged in urine; fecal elimination accounts for ~30% of metabolites.
Renal (1% unchanged), fecal (33% as metabolites), biliary (minor). Extensive hepatic metabolism; <1% excreted unchanged in urine.
Category A/B
Category C
Antifungal
Antifungal